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aims: The role of the renin–angiotensin system (RAS) in the biology of infantile hemangioma 
(IH) represents an emerging paradigm, particularly the involvement of renin, angiotensin 
converting enzyme, and angiotensin II. This study investigated the expression of cathepsins 
B, D, and G, enzymes that may modulate the RAS, in IH.
Materials and Methods: The expression of cathepsins B, D, and G was examined using 
immunohistochemistry, enzyme activity assays, mass spectrometry, and NanoString gene 
expression assay in IH samples at different phases of development.
results: Immunohistochemical staining showed the expression of cathepsins B, D, and 
G in proliferating and involuted IH samples. This was confirmed at the transcriptional level 
using NanoString gene expression assays. Mass spectrometry confirmed the identification 
of cathepsins D and G in all three phases of IH development, whereas cathepsin B was 
detected in 2/2 proliferating and 1/2 involuting lesions. Enzyme activity assays demon-
strated the activity of cathepsins B and D, but not G, in all phases of IH development.
conclusion: Our data demonstrated the presence of cathepsins B, D, and G in IH. Their 
role in modulating the RAS and the biology of IH offers potential novel targets for the 
management of this tumor.
Keywords: paracrine, renin–angiotensin system, infantile hemangioma, cathepsin, angiotensin converting enzyme
introduction
Infantile hemangioma (IH) affects 4–10% of Caucasian infants (1–3). It typically undergoes rapid 
proliferation during infancy followed by spontaneous slow involution over 1–10 years, often leaving 
a fibro-fatty residuum (4, 5).
Recent data have implicated IH as an embryonic developmental anomaly due to aberrant prolifera-
tion and differentiation of a hemogenic endothelium (6) derived from a primitive mesoderm with a 
neural crest phenotype (7, 8). There is also evidence of a crucial role for the endocrine renin–angio-
tensin system (RAS) with the vasoactive peptide, angiotensin II (ATII), as a key regulator of this 
hemogenic endothelium (9–11). An understanding of the RAS pathway and the control mechanisms 
that govern the downstream production of the ATII (10) is critical in the understanding of the biology 
of this enigmatic condition and the observed efficacy of systemic administration of β-blockers (12) 
and angiotensin converting enzyme inhibitors (ACEi) (13) in the treatment of IH.
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The classical RAS pathway involves the initial conversion of 
angiotensinogen to angiotensin I (ATI) by renin, with its sub-
sequent conversion to ATII by angiotensin converting enzyme 
(ACE) (14) (Figure  1). Recent reports of the observed effect 
of topical β-blockers (15) and the variable effects of systemic 
β-blockers (16) and ACEi (13) for a given dosage on IH have led 
us to speculate on the possibility of non-classical RAS pathways 
acting as bypass mechanisms that contribute to the ultimate 
availability of ATII (17).
We have previously characterized the mast cells within IH and 
shown their abundant expression of chymase (18), thus providing 
evidence for the existence of one critical enzyme involved in a 
non-classical RAS pathway (Figure 1).
In this study, we investigated, within IH, the presence and 
localization of other non-renin and non-ACE pathways involving 
cathepsin B, an enzyme that converts pro-renin to active renin (19, 
20); cathepsin D, a protease that converts angiotensinogen to ATI 
(21, 22); and cathepsin G, a protease with the ability to produce 
ATII from both angiotensinogen and ATI (19, 20) (Figure 1).
Materials and Methods
Proliferating (n = 6), involuting (n = 3), and involuted (n = 6) IH 
samples were obtained from patients aged 4–7 months, 2–4 years, 
and 6–12 years, respectively, according to a protocol approved by 
Figure 1 | The production of angiotensin ii (aTii) involves the 
classical renin–angiotensin system (illustrated in bold letters) and 
paracrine bypass loops involving multiple enzymes (illustrated in 
unbold letters) in that angiotensinogen is converted to angiotensin i 
(aTi) either by cathepsin D or by renin, with renin converted from its 
precursor pro-renin form, by cathepsin B. ATI is then cleaved to form 
ATII by either angiotensin converting enzyme, chymase, or cathepsin G, 
which also can directly convert angiotensinogen to ATII.
the Central Health and Disability Ethics Committee (2 October 
2013; Approval No: 13/CEN/130).
immunohistochemistry
Four μm-thick formalin-fixed paraffin-embedded IH sections of 
proliferating (n = 6) and involuted (n = 6) from 12 patients were 
used for immunohistochemical (IHC) staining. Antigen retrieval 
was performed using sodium citrate (Leica) at 95°C for 15 min. All 
sections underwent single 3,3-diaminobenzidine (DAB) staining 
for the primary antibodies, cathepsin B, 1:200 (Santa Cruz); cath-
epsin D, 1:200 (Leica); cathepsin G, 1:200 (Santa Cruz); tryptase, 
ready to use (Leica), CD34, ready to use (Leica); and GLUT-1, 
1:200 (Cell Marque) with detection using the bond polymer refine 
detection kit (Leica). To confirm dual expression of two proteins, 
selected representative slides of each phase of IH underwent 
immuno-fluorescent (IF) IHC staining with the same primary 
antibodies at the same concentrations, but using an appropriate 
secondary antibody for detection (donkey anti-mouse Alexa-488 
or donkey anti-rabbit Alexa 594, Life Technologies, NZ, USA). All 
antibodies were diluted in Bond primary antibody diluent (Leica), 
and all DAB and IF IHC staining were performed on the Leica 
Bond Rx auto-stainer (Leica, Australia). IF IHC stained slides were 
mounted using vectashield hardset medium with DAPI (Vector 
Laboratories, CA, USA).
Mass spectrometry
Total protein extracted from proliferating (n =  2), involuting 
(n = 2), and involuted (n = 2) IH tissues from six patients of the 
original cohort was used for mass spectrometry. The tissues were 
homogenized in 150 μL of ice cold RIPA buffer (Sigma-Aldrich) 
containing 1× Complete Protease inhibitor cocktail EDTA-free 
(Roche Life Science) using a Teflon-coated dounce homog-
enizer. After protein quantitation (Qubit® 2.0 Fluorometer, Life 
Technologies, San Diego, CA, USA), 100 mg of total protein from 
each sample was precipitated overnight at −20°C (ProteoExtract® 
Protein Precipitation Kit, Merck Millipore). The washed protein 
pellets were re-suspended in 50 μL of 5% sodium deoxycholate 
(SDC), 10 mM dithiothreitol, 100 mM TEAB buffer (pH 8.5) 
(Sigma Aldrich), and incubated for 30 min at 80°C. Samples were 
then alkylated for 60 min in the dark using 40 mM iodoaceta-
mide, and diluted to 500 μL final volume in 100  mM TEAB 
buffer (pH 8.5). Proteins were digested overnight at 37°C using 
4  mg trypsin per sample (modified sequencing grade trypsin 
from bovine pancreas; Roche Life Science). SDC removal 
was achieved by formic acid precipitation (1% final volume) 
and centrifugation for 30  min at 13,000 ×  g, and the peptide 
supernatants transferred to fresh microcentrifuge tubes. The SDC 
precipitates were washed with 200 μL of 1% formic acid and 
each wash solution was combined with the previously recovered 
peptide supernatant. Samples were then concentrated to ~10 μL, 
reconstituted to 500 μL in 0.1% formic acid, purified using OMIX 
C18 pipette tips (Agilent Technologies), and prepared for liquid 
chromatography (LC)–MS/MS (mass spectrometry) in 4% 
acetonitrile: 0.1% formic acid.
Liquid chromatography–MS/MS (four technical replicates per 
sample) was performed using an UltiMate 3000 HPLC system 
(Dionex) connected to a LTQ Orbitrap XL mass spectrometer 
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(Thermo Scientific). Thirty-five μL per sample per injection were 
loaded onto an Acclaim PepMap100, C18 column (3 μm, 100 Å, 
75 μm i.d. ×15 cm, Thermo Scientific) (0.3 μL min−1 flow rate), 
and peptides were eluted and analyzed using data-dependent MS/
MS acquisition (90 s exclusion window, top 8 peptides per MS scan 
selected for MS/MS). Raw MS/MS data files were searched against 
a complete human protein database (SwissProt KB, 22 October 
2014, 69689 sequences) using Proteome DiscovererTM V1.4 (Thermo 
Scientific) and Scaffold 4.0 (Proteome Software) to establish protein 
identification and relative protein abundance by spectral counting. 
Peptide assignments were accepted above 90% confidence, and 
protein identification parameters were: protein threshold, 1.0% FDR; 
minimum total spectrum count, 2; peptide threshold, 1.0% FDR.
enzymatic activity
Enzymatic activities of cathepsins B, D, and G were determined 
fluorometrically in snap-frozen proliferating (n = 3), involuting 
(n = 3), and involuted (n = 3) IH samples from nine patients of the 
original cohort, using cathepsin B activity assay kit (Calbiochem), 
cathepsin D activity assay kit (Abcam), and cathepsin G activity 
assay kit (Abcam), respectively. All steps of the procedure were 
performed according to the manufacturers’ protocol. Fluorescence 
was measured in 96-well plate format using the Varioscan plate 
reader (ThermoFisher).
nanostring analysis
Snap-frozen samples of proliferating (n = 6) and involuted (n = 6) 
IH from 12 patients were used to isolate total RNA for NanoString 
nCounterTM Gene Expression Assay (NanoString Technologies, 
Seattle, WA, USA). The RNA was extracted from frozen tissues 
using RNeasy Mini Kit (Qiagen) and quantitated by the NanoDrop 
2000 Spectrophotometer (Thermo Scientific). RNA samples with 
A260/A280 ≥1.9 and A260/A230 ≥1.8 were subjected to the 
NanoString nCounterTM gene expression assay as performed 
by New Zealand Genomics Ltd. (Dunedin, New Zealand), 
according to the manufacturer’s protocol. Probes for the genes 
encoding cathepsin B (CTSB; NM_001908.3), cathepsin D (CTSD; 
NM_001909.3), cathepsin G (CTSG; NM_001911.2), and the 
housekeeping genes CLTC (NM_004859.2), GUSB (NM_00181.3), 
HPRT1 (NM_00194.1), and PGK1 (NM_000291.3) were manufac-
tured by NanoString Technologies (Seattle, WA, USA). Raw data 
were analyzed by nSolverTM software (NanoString Technologies, 
Seattle, WA, USA) using standard settings and were normalized 
against the housekeeping genes.
image analysis
All confocal images were captured using the Olympus FV1200 
confocal microscope (Tokyo, Japan). All bright field images were 
captured using the Olympus BX53 microscope fitted with an 
Olympus DP21 digital camera (Tokyo, Japan).
statistical analyses
Statistical analyses were performed using the Kruskal–Wallis 
one-way analysis of variance for independent samples, using IBM 
SPSS (Version 22). This assigns ranks to the data, with p < 0.05 
considered statistically significant.
results
immunohistochemical staining
The microvessels of IH are composed of a distinct inner endothe-
lial and a concentric outer pericyte layer (23, 24). All IH lesions 
used in the experiments were confirmed by the expression of 
GLUT-1 (data not shown), the marker used to differentiate IH 
from other vascular anomalies (23). The expression of cathepsin B 
(Figures 2A,B, red) was demonstrated in cells of the endothelium 
(Figures 2A,B, thick arrows), expressing CD34 (Figures 2A,B, 
green), as well as in the cells of the interstitium (Figures 2A,B, 
thin arrows), in both proliferating (Figure  2A) and involuted 
(Figure 2B) IH samples. This was in contrast to the expression 
of cathepsin D (Figures 2C,D, green), which was predominantly 
expressed by cells in the interstitium, away from the endothe-
lium expressing GLUT-1 (Figures  2C,D, red) in proliferating 
(Figure 2C) and involuted (Figure 2D) IH. A similar staining 
pattern was also demonstrated for cathepsin G (Figures 2E,F, 
red) in cells in the interstitium, distinct from the endothelium 
expressing CD34 (Figures  2E,F, green), in both proliferating 
(Figure 2E) and involuted (Figure 2F) IH samples.
To further characterize the expression profile of the interstitial 
population expressing the cathepsins within proliferating IH, 
dual staining was performed for cathepsin B (Figure  3A, red) 
and cathepsin D (Figure 3A, green) confirming the expression by 
two distinct cellular populations. The expression of cathepsin G 
has previously been reported in mast cells (25). Using tryptase as 
a marker for mast cells, we performed dual staining for tryptase 
(Figure  3B, green) and cathepsin G (Figure  3B, red), which 
confirmed the expression of cathepsin G on the tryptase+ mast 
cells in the interstitium.
Mass spectrometry
Liquid chromatography–MS/MS analysis confirmed the pres-
ence of cathepsin B in proliferating and involuting IH tissues 
only, with cathepsins D and G identified throughout all three 
phases of IH. Spectral counting demonstrated that the relative 
abundance of cathepsin B was consistent between proliferating 
and involuting IH tissue (Figure 4), whereas cathepsins D and 
G remained relatively unchanged across all three phases. The 
protein identification values are summarized in Table S1 in 
Supplementary Material.
enzymatic activity
Enzymatic assays performed to determine the presence of activi-
ties for cathepsins B, D, and G in IH samples in all three phases 
of IH development confirmed the activity of both cathepsins B 
and D (Figure 5). Comparing the activity of cathepsin B across 
all three phases, there was statistical significance (p =  0.029) 
in the differences between the levels of activity in involuting 
compared to both proliferating and involuted IH samples used. 
Analysis of the enzyme activity of cathepsin D revealed statisti-
cally significant (p =  0.021) increase in the levels of activity 
Figure 2 | confocal immunofluorescent immunohistochemical images 
of proliferating (a, c, e) and involuted (B, D, F) ih samples. The 
expression of cathepsin B [(a,B), red] is seen on the endothelium [(a,B), thick 
arrows] as well as cells in the interstitium [(a,B), thin arrows] in proliferating and 
involuted IH. Cathepsin D was predominantly localized to cells of the 
interstitium [(c,D), green] and appeared distinct from the endothelium 
expressing GLUT-1 [(c,D), red]. Similarly, the expression of cathepsin G  
[(e,F), red] was also restricted to cells of the interstitium and is independent of 
the CD34+ endothelium [(e,F), green]. Cell nuclei [(a–F), blue] are stained with 
4′,6′-diamidino-2-phenylindole dilactate.
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from proliferating to involuting and from involuting to involuted 
phases of IH. Interestingly, the enzymatic activity of cathepsin 
G was barely detectable in all IH tissues examined (data not 
shown).
nanostring assay
To support the translational abundance of cathepsins B, D, and 
G examined in this study, we used transcriptional profiling of the 
tissue samples for corresponding levels of mRNA at all phases of 
Figure 4 | cathepsins B and D enzyme activity in infantile 
hemangioma tissues with enzyme activity assays performed in 
proliferating (n = 3), involuting (n = 3), and involuted (n = 3) samples. 
The data were subjected to statistical analysis using the Kruskal–Wallis 
one-way analysis of variance for independent samples. P < 0.05 was 
considered as statistically significant.
Figure 3 | confocal immunofluorescent immunohistochemical images 
of proliferating ih showing distinct interstitial cellular populations 
expressing cathepsin B [red, (a)] and cathepsin D [green, (a)]. Cathepsin 
G [red, (B)] was expressed by the phenotypic mast cells that also expressed 
tryptase [(B), green)]. Cell nuclei [(a,B), blue] are stained with 4′,6′-diamidino-
2-phenylindole dilactate.
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IH development. The levels of mRNA for both cathepsins B and 
D were relatively high. This was in comparison with significantly 
lower levels for cathepsin G mRNA (Figure 6). No statistically 
significant differences of cathepsin D and cathepsin G mRNA levels 
were observed between proliferating and involuted IH samples. 
However, for cathepsin B, the involuted IH samples expressed 
significantly higher (p = 0.007) amounts of corresponding mRNA 
compared to proliferating samples.
Discussion
We have recently demonstrated the crucial role for ATII in the 
biology of IH (10). ATII, a vasoactive peptide, is the downstream 
product of the RAS pathway, which in part accounts for the pro-
gramed biological behavior of IH (9, 26) and the observed efficacy 
of the systemic administration of β-blockers (9) and captopril, an 
ACEi (13).
More recent reports have shown variable effects of sys-
temic β-blockers for a given dosage (16) on IH. However, it 
is not possible to judge from the reports the traits of the slow 
responding lesions, as to whether location, multiplicity, or 
the size/volume of the lesions are determining factors for the 
relative responses. We have also observed variable effects of 
low-dose captopril on proliferating IH in patients for a given 
dosage (13). This may be due to the relatively low dosage of 
captopril used in the trial with possible spill-over of production 
Figure 6 | cathepsins B, D, and g mrna levels in infantile 
hemangioma (ih) tissues. NanoString nCounter Gene Expression assay 
with specific probes for CTHB, CTHG, and CTHD genes was performed 
using proliferating (n = 6) and involuted (n = 6) IH tissue samples. The data 
are presented as mean ± SD, and statistical analyses showed no 
significance.
Figure 5 | relative protein abundance of cathepsins B, D, and g 
extracted from proliferating (n = 2), involuting (n = 2), and involuted 
(n = 2) infantile hemangioma (ih). Proteome Discoverer™ V1.4 and Scaffold 
4.0 were used to establish relative protein abundance by spectral counting. 
Relative protein abundance of all three cathepsins was unchanged between all 
three IH samples.
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of the downstream ATII, to innately high circulating of renin, 
or potential existence of paracrine, non-classical, RAS bypass 
pathways (Figure 1) (17). The latter possibility forms the basis 
of this investigation.
The final production of ATII results from the classical RAS path-
way that depends on the presence of both renin and ACE but also the 
non-renin/non-ACE pathways involving a number of proteases (17, 
27). Chymase, an enzyme critical for the conversion of ATI to ATII 
(Figure 1) (28) has previously been demonstrated to be expressed by 
the mast cells within IH (18). These phenotypic mast cells have been 
more recently identified to possess a primitive myeloid phenotype by 
their expression of the stem cell marker, Nanog, in the proliferating 
and involuting, but not involuted IH (29).
Our finding of the presence of cathepsins B, D, and G at 
both transcriptional and translational levels within IH, and the 
previous demonstration of the abundance of chymase (18) and 
ACE (9) suggests a system primed for downstream ATII produc-
tion (Figure 1). It is intriguing that, although we have detected 
the presence of cathepsin G at both the transcriptional and 
translational levels, the enzymatic activity was not significant. 
It is possible that the presence of inhibitors of cathepsin G, such 
as serpins (30), may contribute to this apparent inconsistency, 
which is currently the topic of further investigation. We were 
unable to detect the presence of cathepsin B in the involuted 
IH samples by mass spectrometry, despite its presence being 
detected on IHC staining and high transcriptional levels. We 
infer a sampling error and/or low sample numbers leading to the 
inability to detect it rather than its absence. Our initial model of 
the classical RAS (31), with the high levels of circulating renin, 
presumed that IH has access to both the circulating endocrine 
angiotensinogen and ATI peptides (Figure 1). However, multiple 
paracrine proteases demonstrated in this study may also promote 
the production of ATII. This provides potential bypass mecha-
nisms for IH to produce ATII that potentially promotes tumor 
growth (14), despite β-blockade or ACE inhibition (Figure 1).
The presence of cathepsins B, D, and G and chymase offers pos-
sible explanations that certain lesions are relatively more refractory 
to β-blockade and ACE inhibition. ACE inhibition results in an 
accumulation of ATI, which can potentially be converted to ATII 
by chymase produced by mast cells. This study demonstrates the 
presence of potential shunting/shuffling of upstream precursor 
peptides, through these non-classical RAS pathways, which we 
infer, may subsequently play a more prominent role once the 
classical RAS undergoes blockade.
This report reveals the expression of cathepsins B, D, and G in 
IH and offers novel insights into their roles in the RAS pathway, 
in this tumor. It provides understanding of the potential multiple 
pathways contributing to the ultimate levels of the vasoactive 
peptide, ATII, and highlights the complexity of β-blockade or 
ACE inhibition in the treatment of this tumor. Further inves-
tigation of the functional roles of cathepsins B, D, and G, and 
chymase, in the complex interplay of enzymes involved in the 
RAS pathway is needed to unravel their precise role of RAS in 
the biology of IH.
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Key Messages
1.  This report highlights the presence of cathepsins B, D, and 
G in infantile hemangioma (IH).
2.  Cathepsins B, D, and G within IH may play a crucial role in 
the production of angiotensin peptides in proliferating lH.
3.  The presence of potential bypass mechanisms for the produc-
tion of angiotensin peptides highlights the role for the RAS 
in proliferating IH.
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